9860.Hk
The company operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the provision of healthcare services and pharmaceutical products.
Business. The company operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the provision of healthcare services and pharmaceutical products.
Analyst recommendations
4 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, primarily engaged in pharmaceuticals and healthcare facilities and services, generating revenue through the provision of healthcare services and pharmaceutical products.
The company's capital structure is characterized by a debt-to-equity ratio of 0.96, indicating a moderate level of leverage. The liquidity position is assessed as medium, with a current ratio of 1.44, suggesting the company has sufficient short-term assets to cover its short-term liabilities. The company's market price is 4.45 CNY, and its market capitalization is 3.23 billion CNY, with a price-to-earnings ratio of 175.09, which is notably high.
In terms of profitability, the company's return on equity is 1.07%, and its return on assets is 0.38%, both of which are relatively low. The company's gross profit margin is 36.1%, and its operating margin is 3.8%, indicating that the company is generating modest profits relative to its revenue. These metrics suggest that the company is underperforming compared to industry standards.
The company's revenue is primarily derived from its operations in the healthcare sector, with a significant portion coming from pharmaceuticals and healthcare services. There is no specific information provided on geographic revenue concentration, but the company's operations are likely concentrated in its primary market.
The company's growth trajectory is not clearly defined, as there is no specific data provided on future revenue projections. However, the company's free cash flow is 99.42 million CNY, and its capital expenditure is -108.25 million CNY, indicating that the company is investing in its operations. The company's operating cash flow is 225.74 million CNY, which is positive and suggests that the company is generating sufficient cash from its operations.
The company's risk assessment indicates a medium level of liquidity risk and a low level of dilution risk. The key flag of concern is that the company's net cash is negative after subtracting total debt, which could impact its ability to meet short-term obligations. The company's dilution potential is low, and there are no significant adjustments applied to its valuations.
Recent events and filings do not provide specific details on the company's operations or financial performance. The company's analyst estimates suggest a mean price target of 8.01 CNY, with a median price target of 8.07 CNY, indicating a positive outlook from analysts. The mean recommendation is 1.50, which is a strong buy, with two strong-buy and two buy recommendations.
- The company has a high price-to-earnings ratio, indicating that it is overvalued relative to its earnings.
- The company's return on equity and return on assets are low, suggesting poor profitability.
- The company's liquidity position is moderate, with a current ratio of 1.44.
- The company's free cash flow is positive, indicating that it is generating sufficient cash from its operations.
- Analysts have a positive outlook on the company, with a mean price target significantly higher than the current market price.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,20 |
| Revenue | —no estimate | —no estimate | 3,2B CNY |
| Operating income | —no estimate | —no estimate | 288,5M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 9860.HK Market data — financials · 2026-05-27
- Adicon Holdings Ltd Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Song GaoChief Executive Officer, Executive Director